nach oben

Medical Oncology

Erschienen in:

01.10.2020 | Original Paper

MYH9 suppresses melanoma tumorigenesis, metastasis and regulates tumor microenvironment

verfasst von: Satyendra Kumar Singh, Sunita Sinha, Jyotirmayee Padhan, Nitish Jangde, Rashmi Ray, Vivek Rai

Erschienen in: Medical Oncology | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Non-muscle myosin IIA heavy chain (MYH9) has been implicated in many physiological and pathological functions including cell adhesion, polarity, motility to cancer. However, its role in melanoma remains unexplored. The aim of our study was to evaluate the role of MYH9 in melanoma tumor development and metastasis and further to find out the potential underlying mechanisms. In this study, we evaluated the in vitro migratory and invasive properties and in vivo tumor development and metastasis in C57BL/6 mice by silencing MYH9 in B16F10 melanoma cells. Knocking down MYH9 enhanced migration and invasiveness of B16F10 cells in vitro. Furthermore, MYH9 silencing accelerated tumor growth and metastasis in melanoma subcutaneous and intravenous mouse models. Next, oncogenes analysis revealed epithelial–mesenchymal transition and Erk signaling pathway are being regulated with MYH9 expression. Finally, MYH9 silencing in B16F10 cells modulates the tumor microenvironment by manipulating the leukocytes and macrophages infiltration in tumors. These findings established the opposing role of MYH9 as a tumor suppressor in melanoma suggesting specific MYH9 based approaches in therapeutics.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442.CrossRef

Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Investig Dermatol. 2016;136(6):1161–71. https://doi.org/10.1016/j.jid.2016.01.035.CrossRefPubMed

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–644. https://doi.org/10.1126/science.1203543.CrossRefPubMed

Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275–92. https://doi.org/10.1016/j.cell.2011.09.024.CrossRefPubMedPubMedCentral

Liu Q, Zhang H, Jiang X, Qian C, Liu Z, Luo D. Factors involved in cancer metastasis: a better understanding to “seed and soil” hypothesis. Mol Cancer. 2017;16(1):176. https://doi.org/10.1186/s12943-017-0742-4.CrossRefPubMedPubMedCentral

Bresnick AR. Molecular mechanisms of nonmuscle myosin-II regulation. Curr Opin Cell Biol. 1999;11(1):26–33. https://doi.org/10.1016/s0955-0674(99)80004-0.CrossRefPubMed

Bondzie PA, Chen HA, Cao MZ, Tomolonis JA, He F, Pollak MR, et al. Non-muscle myosin-IIA is critical for podocyte f-actin organization, contractility, and attenuation of cell motility. Cytoskeleton (Hoboken). 2016;73(8):377–95. https://doi.org/10.1002/cm.21313.CrossRef

Betapudi V, Gokulrangan G, Chance MR, Egelhoff TT. A proteomic study of myosin II motor proteins during tumor cell migration. J Mol Biol. 2011;407(5):673–86. https://doi.org/10.1016/j.jmb.2011.02.010.CrossRefPubMedPubMedCentral

Hirata N, Takahashi M, Yazawa M. Diphosphorylation of regulatory light chain of myosin IIA is responsible for proper cell spreading. Biochem Biophys Res Commun. 2009;381(4):682–7. https://doi.org/10.1016/j.bbrc.2009.02.121.CrossRefPubMed

10.

Beadle C, Assanah MC, Monzo P, Vallee R, Rosenfeld SS, Canoll P. The role of myosin II in glioma invasion of the brain. Mol Biol Cell. 2008;19(8):3357–68. https://doi.org/10.1091/mbc.E08-03-0319.CrossRefPubMedPubMedCentral

11.

Sabbir MG, Dillon R, Mowat MR. Dlc1 interaction with non-muscle myosin heavy chain II-A (Myh9) and Rac1 activation. Biol Open. 2016;5(4):452–60. https://doi.org/10.1242/bio.015859.CrossRefPubMedPubMedCentral

12.

Derycke L, Stove C, Vercoutter-Edouart AS, De Wever O, Dolle L, Colpaert N, et al. The role of non-muscle myosin IIA in aggregation and invasion of human MCF-7 breast cancer cells. Int J Dev Biol. 2011;55(7–9):835–40. https://doi.org/10.1387/ijdb.113336ld.CrossRefPubMed

13.

Betapudi V, Licate LS, Egelhoff TT. Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration. Cancer Res. 2006;66(9):4725–33. https://doi.org/10.1158/0008-5472.can-05-4236.CrossRefPubMed

14.

Katono K, Sato Y, Jiang SX, Kobayashi M, Nagashio R, Ryuge S, et al. Prognostic significance of MYH9 expression in resected non-small cell lung cancer. PLoS One. 2015;10(3):e0121460. https://doi.org/10.1371/journal.pone.0121460.CrossRefPubMedPubMedCentral

15.

Maeda J, Hirano T, Ogiwara A, Akimoto S, Kawakami T, Fukui Y, et al. Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br J Cancer. 2008;98(3):596–603. https://doi.org/10.1038/sj.bjc.6604197.CrossRefPubMedPubMedCentral

16.

Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol. 2009;10(11):778–90. https://doi.org/10.1038/nrm2786.CrossRefPubMedPubMedCentral

17.

Conti MA, Adelstein RS. Nonmuscle myosin II moves in new directions. J Cell Sci. 2008;121(Pt 1):11–8. https://doi.org/10.1242/jcs.007112.CrossRefPubMed

18.

Schramek D, Sendoel A, Segal JP, Beronja S, Heller E, Oristian D, et al. Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science. 2014;343(6168):309–13. https://doi.org/10.1126/science.1248627.CrossRefPubMedPubMedCentral

19.

Xia ZK, Yuan YC, Yin N, Yin BL, Tan ZP, Hu YR. Nonmuscle myosin IIA is associated with poor prognosis of esophageal squamous cancer. Dis Esophagus. 2012;25(5):427–36. https://doi.org/10.1111/j.1442-2050.2011.01261.x.CrossRefPubMed

20.

Shin DH, Kim OH, Jun HS, Kang MK. Inhibitory effect of capsaicin on B16-F10 melanoma cell migration via the phosphatidylinositol 3-kinase/Akt/Rac1 signal pathway. Exp Mol Med. 2008;40(5):486–94. https://doi.org/10.3858/emm.2008.40.5.486.CrossRefPubMedPubMedCentral

21.

Zhao K, Wei L, Hui H, Dai Q, You QD, Guo QL, et al. Wogonin suppresses melanoma cell B16-F10 invasion and migration by inhibiting Ras-medicated pathways. PLoS One. 2014;9(9):e106458. https://doi.org/10.1371/journal.pone.0106458.CrossRefPubMedPubMedCentral

22.

Koszalka P, Pryszlak A, Golunska M, Kolasa J, Stasilojc G, Skladanowski AC, et al. Inhibition of CD73 stimulates the migration and invasion of B16F10 melanoma cells in vitro, but results in impaired angiogenesis and reduced melanoma growth in vivo. Oncol Rep. 2014;31(2):819–27. https://doi.org/10.3892/or.2013.2883.CrossRefPubMed

23.

Razak NA, Abu N, Ho WY, Zamberi NR, Tan SW, Alitheen NB, et al. Cytotoxicity of eupatorin in MCF-7 and MDA-MB-231 human breast cancer cells via cell cycle arrest, anti-angiogenesis and induction of apoptosis. Sci Rep. 2019;9(1):1514. https://doi.org/10.1038/s41598-018-37796-w.CrossRefPubMedPubMedCentral

24.

Coaxum SD, Tiedeken J, Garrett-Mayer E, Myers J, Rosenzweig SA, Neskey DM. The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer. Oncotarget. 2017;8(14):22991–3007. https://doi.org/10.18632/oncotarget.14967.CrossRefPubMedPubMedCentral

25.

Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006;66(17):8319–26. https://doi.org/10.1158/0008-5472.can-06-0410.CrossRefPubMed

26.

Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol. 1999;147(3):631–44. https://doi.org/10.1083/jcb.147.3.631.CrossRefPubMedPubMedCentral

27.

Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 2003;5(6):R217–22. https://doi.org/10.1186/bcr651.CrossRefPubMedPubMedCentral

28.

Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktas M, et al. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol. 2011;179(1):400–10. https://doi.org/10.1016/j.ajpath.2011.03.028.CrossRefPubMedPubMedCentral

29.

Lewis-Tuffin LJ, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, et al. Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One. 2010;5(10):e13665. https://doi.org/10.1371/journal.pone.0013665.CrossRefPubMedPubMedCentral

30.

Reddy P, Liu L, Ren C, Lindgren P, Boman K, Shen Y, et al. Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. Mol Endocrinol. 2005;19(10):2564–78. https://doi.org/10.1210/me.2004-0342.CrossRefPubMed

31.

Kwak T, Drews-Elger K, Ergonul A, Miller PC, Braley A, Hwang GH, et al. Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene. 2017;36(11):1559–722. https://doi.org/10.1038/onc.2016.324.CrossRefPubMed

32.

Schiavoni G, Gabriele L, Mattei F. The tumor microenvironment: a pitch for multiple players. Front Oncol. 2013;3:90. https://doi.org/10.3389/fonc.2013.00090.CrossRefPubMedPubMedCentral

33.

Nasser MW, Wani NA, Ahirwar DK, Powell CA, Ravi J, Elbaz M, et al. RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res. 2015;75(6):974–85. https://doi.org/10.1158/0008-5472.can-14-2161.CrossRefPubMedPubMedCentral

34.

Furudate S, Fujimura T, Kambayashi Y, Kakizaki A, Hidaka T, Aiba S. Immunomodulatory effect of imiquimod through CCL22 produced by tumor-associated macrophages in B16F10 melanomas. Anticancer Res. 2017;37(7):3461–71. https://doi.org/10.21873/anticanres.11714.CrossRefPubMed

35.

Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. 2019;35(4):588–602.e10. https://doi.org/10.1016/j.ccell.2019.02.009.CrossRefPubMedPubMedCentral

36.

Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12(1):76. https://doi.org/10.1186/s13045-019-0760-3.CrossRefPubMedPubMedCentral

Titel: MYH9 suppresses melanoma tumorigenesis, metastasis and regulates tumor microenvironment
verfasst von: Satyendra Kumar Singh
Sunita Sinha
Jyotirmayee Padhan
Nitish Jangde
Rashmi Ray
Vivek Rai
Publikationsdatum: 01.10.2020
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 10/2020
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-020-01413-6

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

MYH9 suppresses melanoma tumorigenesis, metastasis and regulates tumor microenvironment

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2020

Letter to the editor regarding “A randomized controlled trial: comparing extracorporeal shock wave therapy versus local corticosteroid injection for the treatment of carpal tunnel syndrome”

Associated analysis of PER1/TUBB2B with endometrial cancer development caused by circadian rhythm disorders

Transcription factor YY1 mediates epithelial–mesenchymal transition through the TGFβ signaling pathway in bladder cancer

Restraint stress abates the antioxidant potential of melatonin on dimethyl benz (a) anthracene (DMBA) induced carcinogenesis

Head and neck radiotherapy amid the COVID-19 pandemic: practice recommendations of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie